The University of Southampton
University of Southampton Institutional Repository

SIP1/ZEB2-induced epithelial mesenchymal transition promotes metastasis and alters chemokine (C-C motif) ligand 5 expression to modulate the tumour microenvironment in colorectal cancer

SIP1/ZEB2-induced epithelial mesenchymal transition promotes metastasis and alters chemokine (C-C motif) ligand 5 expression to modulate the tumour microenvironment in colorectal cancer
SIP1/ZEB2-induced epithelial mesenchymal transition promotes metastasis and alters chemokine (C-C motif) ligand 5 expression to modulate the tumour microenvironment in colorectal cancer
Epithelial mesenchymal transition (EMT) is a critical trans-differentiation program driving cancer metastasis. Patients showing signs of invasive cancer or the presence of distant metastasis have a poor prognosis. Another well-known feature of decreased cancer-associated survival is the lack of anti-cancer immune responses. Thus I hypothesized that the EMT and anti-tumor response could be linked via altered secretion of soluble factors by metastatic cells.

Colorectal cancer (CRC) cell lines and SIP1-inducible DLD cells were grown in DMEM. The induction of the SIP1 gene was carried out using doxycycline for 3 days. The EMT status of the CRC cell lines were assessed by preforming western blotting, immunofluorescence and RT-PCR for EMT biomarkers. Cytokine/chemokine expression in SIP1 inducible DLD cells was analyzed using commercially-available antibody arrays. Validation of the selected chemokine (CCL5) was carried out using sandwich ELISA as well as RT-PCR, with the CCL5 expression level analysed in a panel of CRC cell lines using the same techniques. The CCL5 promoter was then cloned into pGL3. The mechanism of action of ZEB1/2 on the CCL5 promoter was studied by luciferace assay and chromatin immunoprecipitation (ChIP). CCL5 coding region was cloned into pcDNA3.1 and stably transfected into DLD-1 cells. DLD-1 cells over-expressing CCL5/RANTES were injected orthotopically into SCID mice, and metastasis was investigated by immunohistochemistry (IHC). The relationship between infiltrating T lymphocytes (TILs) and the expression of both CCL5/RANTES and SIP1 was studied in 75 CRC patients by IHC and tissue micrroarray.

The results of evaluating EMT status categorised 13 CRC cell lines as epithelial, intermediate epithelial, intermediate mesechymal and mesenchymal. Cytokine/chemokine antibody arrays showed a significant increase in CCL5/RANTES in induced DLD-SIP1 cells. ELISA, multiplex assays and RT-PCR confirmed the increased secretion of CCL5/RANTES in the induced DLDSIP1 cells. The CRC cell line panel showed that the average level of secreted CCL5/RANTES from mesenchymal CRC cells was significantly more than in epithelial cells (639.7 ± 175 vs 107.6 ± 30 pg/ml, respectively; p=0.0075). mRNA expression profiling confirmed this finding from the CRC panel. Promoter studies showed that ZEB1/2 bind to CCL5 promoter, thus activating CCL5 gene expression. No metastatic spread for of DLD-1 cells overexpressing CCL5/RANTES was observed when orthotopically injected into SCID mice.

Our data shows that CCL5/RANTES is up-regulated by EMT-inducing transcription factor SIP1, and mesenchymal (metastatic) CRC cells secrete significantly more CCL5/RANTES compared to epithelial (non-metastatic) cells. Furthermore, abundant secretion of CCL5/RANTES might be a crucial regulator of immune infiltration in CRC, but not a direct inducer of metastasis, and that needs to be futher investigated. Inhibiting CCL5 activity in metastatic CRC may have a therapeutic potential.
University of Southampton
Al Saihati, Hajir
9d4239e9-6da5-412e-8cff-7aa125c0d438
Al Saihati, Hajir
9d4239e9-6da5-412e-8cff-7aa125c0d438
Bullock, Marc
e060d2b2-5e6f-449b-b8ae-f411b5a396c2

Al Saihati, Hajir (2016) SIP1/ZEB2-induced epithelial mesenchymal transition promotes metastasis and alters chemokine (C-C motif) ligand 5 expression to modulate the tumour microenvironment in colorectal cancer. University of Southampton, Doctoral Thesis, 276pp.

Record type: Thesis (Doctoral)

Abstract

Epithelial mesenchymal transition (EMT) is a critical trans-differentiation program driving cancer metastasis. Patients showing signs of invasive cancer or the presence of distant metastasis have a poor prognosis. Another well-known feature of decreased cancer-associated survival is the lack of anti-cancer immune responses. Thus I hypothesized that the EMT and anti-tumor response could be linked via altered secretion of soluble factors by metastatic cells.

Colorectal cancer (CRC) cell lines and SIP1-inducible DLD cells were grown in DMEM. The induction of the SIP1 gene was carried out using doxycycline for 3 days. The EMT status of the CRC cell lines were assessed by preforming western blotting, immunofluorescence and RT-PCR for EMT biomarkers. Cytokine/chemokine expression in SIP1 inducible DLD cells was analyzed using commercially-available antibody arrays. Validation of the selected chemokine (CCL5) was carried out using sandwich ELISA as well as RT-PCR, with the CCL5 expression level analysed in a panel of CRC cell lines using the same techniques. The CCL5 promoter was then cloned into pGL3. The mechanism of action of ZEB1/2 on the CCL5 promoter was studied by luciferace assay and chromatin immunoprecipitation (ChIP). CCL5 coding region was cloned into pcDNA3.1 and stably transfected into DLD-1 cells. DLD-1 cells over-expressing CCL5/RANTES were injected orthotopically into SCID mice, and metastasis was investigated by immunohistochemistry (IHC). The relationship between infiltrating T lymphocytes (TILs) and the expression of both CCL5/RANTES and SIP1 was studied in 75 CRC patients by IHC and tissue micrroarray.

The results of evaluating EMT status categorised 13 CRC cell lines as epithelial, intermediate epithelial, intermediate mesechymal and mesenchymal. Cytokine/chemokine antibody arrays showed a significant increase in CCL5/RANTES in induced DLD-SIP1 cells. ELISA, multiplex assays and RT-PCR confirmed the increased secretion of CCL5/RANTES in the induced DLDSIP1 cells. The CRC cell line panel showed that the average level of secreted CCL5/RANTES from mesenchymal CRC cells was significantly more than in epithelial cells (639.7 ± 175 vs 107.6 ± 30 pg/ml, respectively; p=0.0075). mRNA expression profiling confirmed this finding from the CRC panel. Promoter studies showed that ZEB1/2 bind to CCL5 promoter, thus activating CCL5 gene expression. No metastatic spread for of DLD-1 cells overexpressing CCL5/RANTES was observed when orthotopically injected into SCID mice.

Our data shows that CCL5/RANTES is up-regulated by EMT-inducing transcription factor SIP1, and mesenchymal (metastatic) CRC cells secrete significantly more CCL5/RANTES compared to epithelial (non-metastatic) cells. Furthermore, abundant secretion of CCL5/RANTES might be a crucial regulator of immune infiltration in CRC, but not a direct inducer of metastasis, and that needs to be futher investigated. Inhibiting CCL5 activity in metastatic CRC may have a therapeutic potential.

Text
Hajjir AlSaihati PhD thesis 2016 ID 24501093 - Version of Record
Available under License University of Southampton Thesis Licence.
Download (8MB)

More information

Published date: July 2016

Identifiers

Local EPrints ID: 417395
URI: http://eprints.soton.ac.uk/id/eprint/417395
PURE UUID: 14fab447-7be8-475a-b5ed-b6259f92e998

Catalogue record

Date deposited: 30 Jan 2018 17:31
Last modified: 13 Mar 2019 19:07

Export record

Contributors

Author: Hajir Al Saihati
Thesis advisor: Marc Bullock

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×